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Abstract
Liver steatosis is a frequent histological feature in patients chronically infected with hepatitis C virus (HCV). The
relationship between HCV and hepatic steatosis seems to be the result of both epigenetic and genetic factors. In
vivo and in vitro studies have shown that HCV can alter intrahepatic lipid metabolism by affecting lipid synthesis,
oxidative stress, lipid peroxidation, insulin resistance and the assembly and secretion of VLDL. Many studies suggest
that HCV-related steatosis might be the result of a direct interaction between the virus and MTP. It has been
demonstrated that MTP is critical for the secretion of HCV particles and that inhibition of its lipid transfer activity
reduces HCV production. However, higher degrees of hepatic steatosis were found in chronic hepatitis C patients
carrying the T allele of MTP -493G/T polymorphism that seems to be associated with increased MTP transcription.
We propose here that liver steatosis in hepatitis C could be a storage disease induced by the effects of the virus
and of its proteins on the intracellular lipid machinery and on MTP. Available data support the hypothesis that HCV
may modulate MTP expression and activity through a number of mechanisms such as inhibition of its activity and
transcriptional control. Initial up regulation could favour propagation of HCV while down regulation in chronic
phase could cause impairment of triglyceride secretion and excessive lipid accumulation, with abnormal lipid dro-
plets facilitating the “storage” of virus particles for persistent infection.
Introduction
Hepatic steatosis, defined as excessive lipid accumula-
tion in the cytoplasm of hepatocytes, is a frequent histo-
logical feature in patients with chronic hepatitis C
(CHC) infection [1-3]. Histological examinations show
that up to 50% of these patients have variable degrees of
hepatic steatosis [4], even in the absence of other possi-
ble steatogenic factors, like alcohol, drugs or metabolic
syndrome [5]. Early electron microscopy studies con-
ducted in experimentally infected chimps or parenterally
infected humans with non A and non B hepatitis
showed presence of abnormal cytoplasmic vesicular
changes [6]. In hepatitis C Virus (HCV) infected patients
liver steatosis is mainly macrovesicular [7] and is located
in the periportal area rather than in the centrilobular
area [8], in contrast to what is observed in non-alcoholic
fatty liver disease (NAFLD) and in alcoholic liver dis-
ease. Prevalence of liver steatosis in HCV patients is sig-
nificantly higher when compared to patients with other
forms of chronic liver disease such as hepatitis B or
autoimmune hepatitis, suggesting a direct effect of HCV
replication in the development of excess fat accumula-
tion in the liver [9-11]. This is also supported by the
observation that the degree of liver steatosis is directly
related to the level of HCV replication as measured by
serum HCV RNA, at least in patients with HCV-3 infec-
tion, in the absence of confounding metabolic causes of
steatosis [12,13]. Understanding mechanisms that cause
hepatic steatosis in the HCV infected patients has been
made difficult due to the co-existence of several con-
founding metabolic cofactors. Patients with CHC may
develop hepatic steatosis as a consequence of concomi-
tant metabolic syndrome, possibly associated with type 2
diabetes, obesity or increased body mass index (BMI).
These conditions are quite frequently observed in HCV
patients and may cause variable degrees of hepatic stea-
tosis by mechanisms that are similar to those of classical
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Indeed, two main types of steatosis have been proposed
to coexist in patients with hepatitis C. The first is a
metabolic type of steatosis that is seen mainly in HCV-1
infected patients and is associated with increased BMI,
hyperlipidemia, and insulin resistance. The second is a
viral type of steatosis that develops also in the absence
of any other steatogenic cofactors and that seems to be
directly triggered by the virus [14].
Furthermore, HCV may also be involved as a cofactor
in the development of the metabolic type of steatosis, as
HCV itself was shown to induce insulin resistance that
consequently may favour the development of hepatic
steatosis [15-17]. Alternatively, HCV may directly affect
genes involved in lipid metabolism leading to fat accu-
mulation in the liver. A direct mechanism is likely to
prevail in patients who develop extensive steatosis in the
absence of insulin resistance as typically, but not exclu-
sively, seen in HCV-3 infected patients. Several lines of
evidence indicate a direct correlation between HCV-3
infection and liver fat accumulation. It is known that
steatosis resolves after reduced virological response
when achieved through antiviral therapy with inter-
feron-alpha and/or ribavirin [18]. We and others have
demonstrated that chronic HCV-3 infection correlates
with lower serum levels of cholesterol, triglyceride and
apolipoprotein B (apoB) compared to patients chroni-
cally infected with other HCV genotypes, suggesting a
profound alteration in lipid and lipoprotein metabolism
in infected hepatocytes [13,19]. Several mechanisms
have been proposed to explain how HCV infection may
induce liver steatosis. In this review, we propose that
HCV-related steatosis might be a viral storage disease
due to a specific interference of HCV with intrahepatic
lipid metabolism involving hepatic microsomal triglycer-
ide transfer protein (MTP) [19].
HCV and Hepatic Steatosis
The current understanding of the mechanisms leading
to lipid accumulation in the cytoplasm of HCV-3
infected hepatocytes is limited, as most of the reported
studies used HCV genotype 1 surrogate systems which
have not been shown to recapitulate the steatogenic
effect in vivo. Further encumbering investigators is the
lack of robust cell culture systems or animal models for
HCV. However, there is strong evidence to suggest that
some HCV proteins, particularly the structural capsid
protein, core, and the non-structural protein, NS5A, can
induce hepatic steatosis by interfering with intracellular
lipid metabolism [20-26]. Hepatoma cell lines over-
e x p r e s s i n gH C Vc o r ep r o t e i n ss h o wi n c r e a s e dl i p i d
accumulation. Abid et al. [27] found that lipid staining
of transfected cells was significantly higher than that of
non-transfected cells for all HCV genotypes tested.
However, the accumulation of triglycerides and cytoplas-
mic lipid droplets was most pronounced with genotype
3a compared to other genotypes. Similar results were
more recently reported by Piodi et al. [28], describing
that the core protein of both HCV genotypes 1b and 3a
has a subcellular localization on the surface of lipid dro-
plets mainly in a macrovesicular pattern. Neutral lipid
accumulation was increased if cells were transfected
with core protein of genotype 3a. This finding is con-
firmed by our experiments in hepatoma cell lines (HuH-
7) transfected with core proteins as shown in Figure 1.
However, as another important finding of this study
[28], core protein seems necessary but not sufficient for
inducing steatosis, as there were no genetic or func-
tional differences between genotype 3a core proteins
from patients with and without HCV-induced steatosis.
These data suggest that interactions between HCV core
protein and lipid droplets could contribute to steatosis.
However, it must be inferred that other host factors and
viral proteins are most likely required in the develop-
ment of HCV related steatosis.
Several mechanisms by which HCV and its proteins
might cause excessive lipid accumulation have been sug-
gested and widely discussed in many reviews. All of the
proposed hypotheses focus on complex interactions
between HCV proteins, lipid synthesis, oxidative stress,
lipid peroxidation, insulin resistance and the assembly
and secretion of apoB-lipoproteins, all of which might
ultimately contribute to the onset of steatosis [29-36].
However, there has been no discussion whether steatosis
might be advantageous for the virus. Why HCV might
want to induce steatosis?
HCV, lipoproteins, and microsomal triglyceride
transfer protein
In infected patients, HCV particles circulate as low-den-
sity lipoprotein (LDL)-virus complexes rich in triglycer-
ides. These so-called lipo-viral particles (LVPs) were
found to contain viral RNA, the viral structural proteins,
core and envelope glycoproteins E1 and E2, but surpris-
ingly also host-derived apolipoproteins B and E (apoB
and apoE) [37], which are the components of apoB-lipo-
proteins [chylomicrons, very low density lipoproteins
(VLDL) and low density lipoproteins (LDL)] [38]. The
reasons for the circulation of the virus with lipoproteins
are not clear. It is possible that this allows the virus to
avoid recognition by leukocytes and also provides a
mechanism to enter cells as a surrogate along with
lipoproteins.
There is strong evidence for an association between
viral infection and lipoprotein metabolism. In cell cul-
ture experiments, HCV subgenomic replicons have been
shown to affect lipoprotein secretion by interfering with
the formation of secretion-competent apoB lipoproteins
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(MTP), an essential chaperone for the biosynthesis of
these lipoproteins [39]. Moreover, apoB seemed to inter-
act with the HCV non-structural protein NS5A, suggest-
ing that apoB may be a target of HCV [40]. Recently,
membrane vesicles containing the HCV replication com-
plex from Huh7 cells that harbour HCV replicons were
isolated [41]. Proteomic analysis of these vesicles
revealed that they were enriched in apoB, apoE, and
MTP, proteins known to associate with lipoproteins
[41]. Interestingly, VLDL synthesis is not required for
HCV RNA replication as HCV RNA can replicate in
HeLa and HEK-293 cells [42,43], which do not produce
VLDL. The reasons for the co-localization of the HCV
replication and proteins involved in lipoprotein metabo-
lism have not yet been elucidated. But, mounting
evidence suggests a requirement for co-assembly or
secretion of VLDL and HCV particles. Using MTP inhi-
bitors and siRNA targeting apoB in a cell culture system
constitutively producing infectious hepatitis C virus,
Huang et al. [41] demonstrated a dependence on the
assembly and secretion of VLDL for HCV production.
While the MTP inhibitor significantly decreased both
extracellular HCV RNA and infectivity, intracellular
RNA levels were unaffected, suggesting the effect was
not due to reduced viral replication, but rather due to
concomitant disruptions of VLDL assembly and secre-
tion with viral assembly and egress. These results were
further confirmed in another study where authors
demonstrated that infectious HCV particles assembly
and secretion is a highly regulated system in which
apoB is a rate-limiting factor and that these two steps
Figure 1 Localization of HCV Core protein to lipid droplets. Huh-7 cells were transfected with a plasmid expressing the capsid (Core)
protein from hepatitis C virus genotype 1 or genotype 3. Following transfection, cells were fixed, neutral lipids were stained by Red-Oil and core
protein was localized by immunofluorescence using an anti-core primary and FITC-conjugated secondary and visualized on a confocal
microscopy: 1A) Merged image demonstrating colocalization of HCV core protein (green) and neutral lipids (red) as intracellular lipid droplets 1B)
FITC localized genotype 3 core protein and 1C) genotype 1.
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inhibition reduces the production of infectious intracel-
lular HCV and its secretion into the extracellular milieu
[44]. More recent experiments [45] have shown that the
secretion of HCV envelope glycoproteins, in the absence
of other viral proteins, also seems to require the
machinery of apoB lipoprotein assembly. Taken
together, these data suggest for MTP-dependent co-
assembly of hepatitis C virions with apoB-containing tri-
glyceride rich lipoproteins.
The clinical evidence that HCV infected patients with
severe steatosis have reduced serum levels of cholesterol
and of apoB is consistent with the hypothesis of a possi-
ble involvement of MTP. The role of MTP in the devel-
opment of HCV-related steatosis has been investigated
using different approaches involving animal models, in
vitro cellular studies and human studies in which others
and we have evaluated MTP genetic variability and gene
and protein expression in HCV patients. The pivotal
observations came from experiments in mouse models:
Shintany et al reported that HCV core transgenic mice
develop insulin resistance associated with massive hepa-
tic steatosis [46]. Using a similar model, Perlemuter et
al. demonstrated that HCV core protein induces hepatic
fat accumulation in mice by inhibiting MTP activity,
leading to impaired secretion of VLDL [47]. The first
study in HCV infected patients was conducted in our
laboratory at the Venetian Institute of Molecular Medi-
cine where we investigated MTP gene expression and
protein activity in liver biopsy specimens from a series
of untreated patients with CHC [19]. Our data indicated
that hepatic MTP gene expression and protein activity
were reduced in the presence of severe steatosis, parti-
cularly in patients infected with HCV-3 and that in
these same cases, impairment in MTP activity showed a
direct relation to levels of HCV replication. We also
observed reduced serum levels of cholesterol and VLDL
in patients with impaired MTP expression and severe
steatosis in hepatocytes. Our results were confirmed in a
more recent study by McPhersons et al [48] who also
demonstrated reduced hepatic expression of MTP
mRNA in HCV infected patients when compared to a
control group of HCV-negative subjects and an inverse
relationship between MTP mRNA levels and degree of
liver steatosis. Moreover, in this study, an inverse rela-
tionship was found also between HCV related steatosis
and liver expression of SREBP-1c and GPAT, two genes
involved in fatty acid and triglyceride synthesis. These
findings support the hypothesis that HCV may cause
accumulation of lipids in infected hepatocytes by per-
turbing hepatic lipid metabolism through a direct inter-
ference with MTP, leading to VLDL/triglyceride
retention. It remains to be determined whether this lipid
retention involves storage of apoB-containing
lipoprotein particles due to abnormal assembly and
secretion or increased assimilation of cytosolic lipid dro-
plets devoid of apoB.
MTP Genetic polymorphism and HCV-related liver
steatosis
Apart from viral and metabolic factors, some specific
host genetic polymorphisms may also play a role in the
pathogenesis of steatosis. Genetic polymorphisms can
modulate the concentration of MTP protein in the endo-
plasmic reticulum, which may have an impact on the
secretion pattern of lipoproteins. A common polymorph-
ism in the promoter region of the MTP gene, -493G/T,
has been characterized functionally. The T allele associ-
ates with increased MTP transcription in vitro and low
serum levels of low-density lipoprotein (LDL) cholesterol
in healthy subjects [49]. The MTP -493G/T polymorph-
ism has been implicated in the susceptibility to develop
steatohepatitis in patients with type II diabetes [50]. The
G allele was more frequently found in patients with non-
alcoholic steatohepatitis (NASH) compared with healthy
controls, and NASH patients with the homozygous geno-
type GG showed more severe degrees of liver steatosis
[51]. More recently, the role of MTP polymorphism has
been investigated in patients chronically infected with
HCV. Initially, the MTP -493G/T polymorphism was
examined among a set of eight genes that have been
reported to have an association with hepatic fibrosis in a
group of 326 patients with CHC [52]. Homozygosity of
either the G or the T allele revealed an adjusted odds
ratio of 4.1 associated with am o r er a p i dp r o g r e s s i o nt o
liver fibrosis. The association between MTP variants and
hepatic steatosis was not tested in this study. Petit et al.
assessed the association between the MTP -493G/T poly-
morphism and steatosis in HCV infected patients for the
first time but no relationship was found [53]. However,
this study included a cohort of only 86 HCV-positive
subjects, with only 39 demonstrating signs of steatosis.
Because of the small sample size, subgroups could not be
analysed separately, and the analysis of data was done on
the whole population and not according to HCV geno-
types. More recently Zampino et al analysed 102 patients
with CHC [54]. Patients infected with HCV-3 and car-
riers of the MTP T allele showed higher degrees of stea-
tosis, higher serum levels of HCV RNA and more
advanced fibrosis. These patients, irrespective of MTP
genotype, had lower serum levels of cholesterol, apoB,
HDL and LDL. No such associations of MTP variants
were seen in patients infected with HCV genotypes other
than HCV-3, probably due to the small sample size of
HCV-1 infected patients, generating a type II error (false
negative).
We recently evaluated the role of MTP -493 G/T
polymorphism in a larger cohort of 298 patients with
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between MTP polymorphism and liver fat accumulation.
Age, BMI, HCV-3 and MTP T allele were independent
risk factors for high grades of steatosis in the total
cohort of HCV patients. In HCV genotype non-3
patients, the MTP T allele was the strongest predictor
for severe steatosis. Thus, severe liver steatosis in HCV
patients correlates with the MTP T allele, in contrast
with what is seen in patients with metabolic syndrome
or type II diabetes [50] or NASH [51], in whom geno-
type MTP -493 GG and the G allele were associated
with more severe steatosis.
These differences can be explained by the different
mechanisms underlying liver fat accumulation in the
two conditions. In patients developing NAFLD/NASH
due to metabolic syndrome/type 2 diabetes, insulin
resistance is associated with increased free fatty acid
delivery to the liver (Figure 2A). Therefore, presence of
MTP -493 G allele, which associates with decreased
MTP transcription, may lead to more severe impairment
of VLDL assembly and secretion, with higher grades of
hepatic steatosis. Thus, in these patients liver steatosis is
a consequence of liver overload by circulating lipids that
can be less efficiently processed by hepatocytes in the
presence of lower MTP activity with the G allele. But,
why should steatosis be associated with decreased MTP
and with T allele in chronic HCV infected patients?
Complex relationship between MTP and HCV
The studies summarized above indicate a complex rela-
tionship between MTP and HCV. First, MTP is essential
for the assembly and secretion of HCV. Second, higher
MTP activity is conducive for infected cells to secrete
HCV-particles. Therefore, intuition predicts that HCV
should up-regulate MTP expression to facilitate its pro-
pagation. This hypothesis has been confirmed by a
recent study [56] in which authors examined the mRNA
levels of a set of lipid metabolism-associated genes in
Figure 2 Possible mechanisms of non-viral and viral steatosis. (A) In NAFLD/NASH, subjects are insulin resistant and have high plasma free
fatty acids (FFA). High FFA delivery to the liver enhances lipoprotein production. Presence of MTP -493G allele, which associates with lower MTP
transcription, may lead to impairments of VLDL secretion and consequently to severe intrahepatic lipid accumulation. (B) In HCV infected
individuals MTP mRNA and protein levels could be a consequence of up/down-regulation of either suppressors or activators of MTP expression
by HCV. During early stages of infection MTP transcriptional activity might be enhanced to facilitate assembly and secretion of infectious HCV-
particles (i). At a later stage of infection (ii), HCV may decrease MTP expression through an up-regulation of some MTP suppressors. This
suppressor might decrease MTP expression. In addition, this suppressor may increase lipogenesis leading to lipid accumulation and hepatic
steatosis. In the presence of T allele at -493 site, decrease in MTP mRNA levels may occur either through a direct binding of some HCV proteins
at the -493 site or through an up-regulation of MTP-suppressor(s) by HCV thus contrasting the enhancing effect of the T allele on MTP gene
expression. We speculate that increased lipid droplets accumulation in hepatocytes may provide a safe environment for HCV latency.
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tological features. Interestingly, it was shown that
expression levels of MTP and other cholesterol-asso-
ciated genes were higher in HCV subjects compared to
control HCV-negative individuals. Therefore, we pro-
pose that HCV might “modulate” transcription of MTP
to facilitate synthesis and secretion of infectious parti-
cles. It is known that MTP transcription is modulated
by different transcription factors that directly bind to
the 5’-flanking 150 bp of the MTP gene promoter
[57-60]. This region contains a negative regulatory
region that includes binding sites for insulin (-124/-116)
and sterol response element binding protein (SREBP)
(-122/-111). The proximal promoter also contains sev-
eral positive regulatory HNF1a ( H N F 1 ) ,L R H - 1 ,a n d
HNF4a (HNF4) binding sites. In addition, a regulatory
DR1 element that binds to PPARa/RXRa,F O X A 2o r
COUP-TFII [57,59-62] has been identified. Except for
the binding of COUP-TFII that acts as a repressor, most
of the transcription factors that bind to DR1 element
act as activators [63]. Many studies have shown that sev-
eral transcription factors involved in MTP transcription
are modulated by HCV (Table 1) supporting the
hypothesis that changes in MTP mRNA and protein
levels could be a consequence of transcriptional regula-
tion during HCV infection.
However, under chronic HCV infection, MTP mRNA
and activity levels decrease [19]. Higher concentration of
HCV proteins might suppress MTP transcription as well
as directly inhibit MTP activity contributing to steatosis.
As discussed before, during early stages of HCV infec-
tion MTP transcriptional activity might be enhanced to
facilitate assembly and secretion of infectious HCV-
particles. Subsequently, virus might undergo intracellular
“storage” in cells for long-term latency. During this pro-
cess, virus might up-regulate lipogenesis and down regu-
late as well as inhibit MTP. These processes would lead
to significant accumulation of lipids (steatosis) in hepa-
tocytes. Virus could then remain associated with these
lipid droplets. Hence, these lipid droplets may provide a
safe heaven for its retention and persistence (Figure 2B).
Furthermore, mechanism(s) underlying higher degrees
of steatosis in the presence of MTP T allele need clarifi-
cations. It is possible that the presence of T allele in the
-493 site might favour an interaction with some HCV
proteins which in turn modulates MTP transcription.
This hypothesis is derived from evidence that specific
binding to the MTP -493 site by nuclear proteins
decreased transcriptional activity of the MTP promoter
[49]. Although in our previous study [55] MTP geno-
types did not significantly modify the corresponding
mRNA expression, it should be noted that with the TT
genotype MTP expression was lower than expected
favouring the hypothesis that a negative regulation
occurs. It is also possible that chronic phase of HCV
infection the presence of T allele in the -493 site may
favour the up-regulation of some MTP suppressors by
HCV thus contrasting the enhancing effect of the T
allele on MTP gene expression.
MTP: A possible new target for the treatment of
HCV infection?
Despite current advances in treatment options, more
effective and safer antiviral agents for hepatitis C are
clearly needed. About 40% of people who are infected
with the hepatitis C virus (HCV) worldwide do not
Table 1 Modulations induced by HCV on the transcription factors involved in the regulation of MTP expression
Study Transcription factor Effect of HCV
Waris G
et al. [69]
SREBP-precursor (Sterol response
element binding protein)
HCV-2 infection leads to activation of three isoforms of SREBPs (forms 1, 1c and 2). Moreover
NS4B and core protein of genotype 3 activates SREBPs through proteolytic cleavage.
Qadri I
et al. [70]
HNF1 and HNF4 (hepatocyte nuclear
factor)
Increased expression of HNF1 and HFN4 mRNA in HCV subgenomic replicon-expressing
Huh.8 cells.
The ability of HCV to induce HNF1 and HNF4 is attributed to 1) increased oxidative stress and
2) direct protein-protein interactions between HCV non-structural component (NS) 5A and
HNF1, leading to enhanced HNF1 DNA binding.
Yamaguchi A
et al. [71]
PPAR-a (peroxisome proliferator-
activated receptor)
In HCV core protein-expressing mice PPAR-a was down-regulated
Kim KH et al.
[72]
PPAR-g The NS5A increases the transcriptional activity and gene expression of PPARg
Tsutsumi T
et al. [73]
Yamaguchi A
et al [71]
RXRa (retinoid X receptor alpha) HCV-Core binds to and activates RXRa
Tanaka N
et al. [74]
PPAR-a, Persistent PPARa activation is essential for development of severe hepatic steatosis and its
progression into hepatocellular carcinoma in the liver of core gene transgenic mice
Dharancy
et al. [75]
PPAR-a, Reduced mRNA levels of PPAR-a in HCV infected patients and in HCV core-expressing HepG2
cells
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current modality (combination of peg-interferon and
ribavirin) in spite of full compliance with dosing and
duration of therapy. Clearly, new therapies are needed
to obliterate this global disease. Potentially effective,
novel therapeutic strategies could exploit the reliance on
and association of the virus with the machinery of host
lipid metabolism. Several recent studies and reviews
have indeed addressed such therapeutic targets
[56,64,65]. Along these lines, pharmacologic inhibition
of MTP might also be a potential antiviral strategy for
HCV [66]. Several MTP inhibitors [67,68] have already
been tested in clinical trials because of their ability to
block VLDL secretion. Long-term treatment with MTP
inhibitors was associated with elevated liver aminotrans-
ferase levels and hepatic fat accumulation [67,68], thus
hampering the approval of these drugs for the treatment
of hypercholesterolemia on a long-term basis. Shorter
treatment regimens reduced the plasma level of VLDL
with only minor adverse effects, which disappeared after
drug removal [68]. It might be of interest to assess
safety and efficacy of short-term treatment with MTP
inhibitors in treating HCV infection.
Conclusions
Understanding the mechanisms underlying liver steato-
sis in HCV infected patients is currently a focus of great
interest and investigations. These studies might greatly
contribute to improved clinical management of this fre-
quent infection. In this regard, many questions remain
unanswered and there is the need to further investigate
the precise mechanisms and complex network of path-
ways by which HCV and its proteins interfere with
hepatic lipid metabolism, particularly with the machin-
ery of assembly and secretion of VLDL.
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